Eli Lilly and Company, maker of Zepbound (tirzepatide) and Foundayo (orforglipron), has said that its investigational drug ...
The partnership will bring together Apollo’s clinical ecosystem with BITS Pilani’s expertise in engineering, technology and ...
The initiative will target hospitals, diagnostic centres, research institutions and smaller healthcare facilities ...
The filing seeks approval of fenebrutinib for adults with relapsing multiple sclerosis (RMS) and primary progressive multiple ...
French biotechnology company Abolis Biotechnologies has launched MINE (Microbial INtelligence Explorer), a new ...
Novel, non-steroidal topical PDE4 inhibitor is approved for adults and pediatric patients aged 2 years and older ...
The study’s primary endpoint was the proportion of patients achieving at least a 75% improvement from baseline in the Eczema ...
The analysis found that people taking Zepbound (tirzepatide) 15 mg lost an average of 4.5% more body weight than those taking Wegovy HD (semaglutide 7.2 mg) after 72 weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results